Failures in Mitochondrial tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family

Ronghua Li, Yuqi Liu, Zongbin Li, Li Yang, Shiwen Wang, Min-Xin Guan

Abstract—We report here on the clinical, genetic, and molecular characterization of 1 Han Chinese family with maternally transmitted hypertension. Three of 7 matrilineal relatives in this 4-generation family exhibited the variable degree of essential hypertension at the age at onset, ranging from 35 to 60 years old. Sequence analysis of the complete mitochondrial DNA in this pedigree identified the novel homoplasmic 4401A>G mutation localizing at the spacer immediately to the 5′ end of tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} genes and 39 other variants belonging to the Asian haplogroup C. The 4401A>G mutation was absent in 242 Han Chinese controls. Approximately 30% reductions in the steady-state levels of tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} were observed in 2 lymphoblastoid cell lines carrying the 4401A>G mutation compared with 2 control cell lines lacking this mutation. Failures in mitochondrial metabolism are apparently a primary contributor to the reduced rate of mitochondrial translation and reductions in the rate of overall respiratory capacity, malate/glutamate-promoted respiration, succinate/glycerol-3-phosphate–promoted respiration, or \(N,N^∗,N^∗-\text{tetramethyl-p-phenylenediamine/ascorbate-promoted respiration in lymphoblastoid cell lines carrying the 4401A>G mutation. The homoplasmic form, mild biochemical defect, late onset, and incomplete penetrance of hypertension in this family suggest that the 4401A>G mutation itself is insufficient to produce a clinical phenotype. Thus, the other modifier factors, eg, nuclear modifier genes and environmental and personal factors, may also contribute to the development of hypertension in these subjects carrying this mutation. These data suggest that mitochondrial dysfunctions, caused by the 4401A>G mutation, are involved in the development of hypertension in this Chinese pedigree. (Hypertension. 2009;54:329-337.)

Key Words: hypertension ■ mitochondria ■ mutation ■ tRNA metabolism ■ maternal inheritance ■ risk factor ■ Chinese

Cardiovascular disease is the leading cause of death in America and the world. In particular, hypertension affects ≈1 billion individuals worldwide and 130 million in China. The etiology of cardiovascular disease is not well understood because of the multifactorial causes. Cardiovascular disease can be caused by a single gene or multifactorial conditions, resulting from interactions between environment and inherited risk factors. Of hereditary factors, the maternal transmissions of cardiovascular disease have been implicated in some pedigrees, suggesting that the mutation(s) in mitochondrial DNA (mtDNA) is one of the molecular bases for this disorder. Recently, several mtDNA point mutations have been identified to be associated with cardiovascular disease. These mutations included the 1555A>G mutation in the 12S ribosomal RNA (tRNA) gene, the 3260A>G and 3303C>T mutations in the tRNA\textsuperscript{Leu(UUR)} gene, the 8348A>G and 8363G>A mutations in the tRNA\textsuperscript{Val} gene, and the 4295A>G, 4300A>G, and 4317A>G mutations in the tRNA\textsuperscript{Glu} gene. Most recently, the 4291T>C mutation in tRNA\textsuperscript{Glu} gene has been associated with a cluster of metabolic defects, including essential hypertension, hypercholesterolemia, and hypomagnesemia in a large family.

With an effort to understand a role of the mitochondrial genome in the pathogenesis of cardiovascular disease in the Chinese population, we have initiated a systematic and extended mutational screening of mtDNA in a large cohort of hypertension subjects in the Geriatric Cardiology Clinic at the Chinese People’s Liberation Army General Hospital. In the present study, we performed the clinical, genetic, and molecular characterizations of another Han Chinese family with maternally transmitted hypertension. Three (2 men/1 woman) of 7 matrilineal relatives in this 4-generation family exhibited the variable severity and age at onset in hypertension. Mutational analysis of the mitochondrial genome has identified the novel 4401A>G mutation in this Chinese family. This novel 4401A>G mutation is localized at the...
junction between the tRNA_{Met} at the heavy strand and tRNA_{Gln} at the light strand.\textsuperscript{19,20} Thus, it is hypothesized that the 4401A>G mutation affects the processing of precursors in these mitochondrial tRNAs. Functional significance of the 4401A>G mutation was evaluated by examining for the steady-state levels of mitochondrial tRNA\textsuperscript{Met}, tRNA\textsuperscript{Gln}, and other tRNAs, including tRNA\textsuperscript{Lys}, tRNA\textsuperscript{Gly}, and tRNA\textsuperscript{Ser}\textsubscript{(UCN)} using lymphoblastoid cell lines derived from 2 affected matrilineal relatives carrying the 4401A>G mutation and from 2 married-in-control individuals lacking the mtDNA mutation. These cell lines were further assessed for the effects of the 4401A>G mutation on the rate of mitochondrial protein synthesis, the endogenous respiration, and substrate-dependent respiration.

Materials and Methods

Subjects

As a part of genetic screening program for hypertension, a Han Chinese family (Figure 1) was ascertained at the Institute of Geriatric Cardiology of the Chinese People’s Liberation Army General Hospital. Informed consent, blood samples, and clinical evaluations were obtained from all of the participating family members, under protocols approved by ethic committee of the Chinese People’s Liberation Army General Hospital and the Cincinnati Children’s Hospital Medical Center Institute Review Board. Members of this family were interviewed and evaluated to identify both personal or medical histories of hypertension and other clinical abnormalities. The 242 control DNA samples were obtained from a panel of unafflicted Han Chinese individuals from the same area.

Measurements of Blood Pressure

Members of this Chinese family underwent a physical examination, laboratory assessment of cardiovascular disease risk factors, and routine electrocardiography. A physician measured the systolic and diastolic blood pressures of subjects using a mercury column sphygmomanometer and a standard protocol. The first and the fifth Korotkoff sounds were taken as indicative of systolic and diastolic blood pressures, respectively. The average of 3 such systolic and diastolic blood pressure readings was taken as the examination blood pressure. Hypertension was defined according to the recommendations of the Sixth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure,\textsuperscript{21} and the World Health Organization-International Society of Hypertension\textsuperscript{22} as a systolic blood pressure of ≥140 mm Hg and/or a diastolic blood pressure of ≥90 mm Hg.

Mutational Analysis of Mitochondrial Genome

Genomic DNA was isolated from whole blood of participants using Puregene DNA Isolation kits (Gentra Systems). The entire mitochondrial genome of the proband II-1 was PCR amplified in 24 overlapping fragments by use of sets of the light-strand and the heavy-strand oligonucleotide primers, as described elsewhere.\textsuperscript{23} Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer using the Big Dye Terminator Cycle sequencing kit. The resultant sequence data were compared with the revised Cambridge reference sequence (GenBank accession No. NC_001807).\textsuperscript{24}

For the quantification of the 4401A>G mutation, the first PCR segments (903 bp) were amplified using genomic DNA as a template and oligodeoxynucleotides corresponding with mtDNA at positions 3777 to 4679 to rule out the coamplification of possible nuclear pseudogenes.\textsuperscript{25} Then, the second PCR product (225 bp) was amplified using the first PCR fragment as a template, and oligodeoxynucleotides corresponding with mtDNA at positions 4243 to 4467 and subsequently digested with the restriction enzyme B\textsubscript{gl}I as the 4401A>G mutation creates the site for this restriction enzyme. Equal amounts of various digested samples were then analyzed by electrophoresis through 7% polyacrylamide gel. The proportions of digested and undigested PCR products were determined by the Image-Quant program after ethidium bromide staining to determine whether 4401A>G mutation is in the homoplasy in these subjects. The allele frequency of the 4401A>G variant was determined by PCR amplification using the genomic DNA derived from 242 Han Chinese controls and subsequent restriction enzyme analysis of PCR products, as described above.

Mitochondrial tRNA Analysis

Lymphoblastoid cell lines were immortalized by transformation with the Epstein-Barr virus, as described elsewhere.\textsuperscript{26} Cell lines derived from 1 proband II-1 and her son III-3 carrying the 4401A>G mutation and 2 Chinese married-in controls (II-2 and III-4) lacking this mutation were grown in RPMI 1640 (Invitrogen), supplemented with 10% FBS. Total mitochondrial RNA were obtained using a TOTALLY RNA kit (Ambion) from mitochondria isolated from lymphoblastoid cell lines (≈4×10\textsuperscript{6} cells) as described previously.\textsuperscript{27} Two micrograms of total mitochondrial RNA were electrophoresed through a 10% polyacrylamide/4.0 mol/L urea gel in Tris-borate-EDTA buffer (after heating the sample at 65°C for 10 minutes) and then electrophoresed onto a positively charged nylon membrane (Roche) for the hybridization analysis with oligodeoxynucleotide probes. For the detection of tRNA\textsuperscript{Met}, tRNA\textsuperscript{Glu}, tRNA\textsuperscript{Lys}, tRNA\textsuperscript{Gly}, and tRNA\textsuperscript{Ser}\textsubscript{UCN}, the following nonradioactive digoxigenin (DIG)-labeled oligodeoxynucleotides specific for each RNA were used: 5'-CATAGGGAGAGGATACAAAAC-3' (tRNA\textsuperscript{Met}); 5'-GAATTTCTGATGAGAATCGAA-3' (tRNA\textsuperscript{Glu}); 5'-TACTCTTTTTTGAATGTT-3' (tRNA\textsuperscript{Lys}); 5'-TACTCTTTTTTGTTGGTTT-3' (tRNA\textsuperscript{Gly}); and 5'-CAAGCCGCCCCAGGCTGGCTC-3' (tRNA\textsuperscript{Ser}\textsubscript{UCN}).\textsuperscript{24} DIG-labeled oligodeoxynucleotides were generated by using a DIG Oligonucleotide Tailing Kit (Roche). The hybridization was carried out as detailed elsewhere.\textsuperscript{28} Quantification of density in each band was made as detailed previously.\textsuperscript{28–30}

Analysis of Mitochondrial Protein Synthesis

Pulse labeling of the cell lines for 30 minutes with [35S]methionine/(\textsuperscript{55}S)cytosine in medium-free DMEM in the presence of emetine, electrophoretic analysis of the translation products, and quantification of radioactivity in the whole-electrophoretic pattern or in individual well-resolved bands was carried out as detailed previously.\textsuperscript{31}

O\textsubscript{2} Consumption Measurements

Rates of O\textsubscript{2} consumption in intact cells were determined with a YSI 5300 oxygraph (Yellow Springs Instruments) on samples of 1×10\textsuperscript{7} cells in 1.5 mL of special DMEM glucose lacking glucose and supplemented with 10% dialyzed FBS.\textsuperscript{25} Polarographic analysis of digitonin-permeabilized cells using different respiratory substrates...
and inhibitors to test the activity of the various respiratory complexes was carried out as detailed previously.33

Results

Clinical Presentation

The proband (II-1) began suffering from hypertension at the age of 60 years. She came to the Geriatric Cardiology Clinic of the Chinese People’s Liberation Army General Hospital for further clinical evaluations at the age of 65 years. Her blood pressure was 180/110 mm Hg. Physical examination, laboratory assessment of cardiovascular disease risk factors, and routine electrocardiography showed no other clinical abnormalities, including diabetes mellitus, vision and hearing impairments, or renal and neurological disorders. Therefore, she exhibited a typical essential hypertension. The family originated from Beijing in northern China, and the majority of family members live in the same area. As shown in Figure 1, this familial history is consistent with a maternal inheritance. None of the offspring of affected fathers had hypertension. Two male matrilineal relatives exhibited hypertension as the sole clinical symptom, whereas other members of this family had normal blood pressure. As shown in Table 1, subject III-3 experienced the hypertension (blood pressure was 140/95 mm Hg) at the age of 35 years. There is no evidence that any member of this family had any other known cause to account for hypertension. Comprehensive family medical histories of these individuals showed no other clinical abnormalities, including diabetes mellitus, vision and hearing impairments, or renal and neurological disorders.

Mitochondrial DNA Analysis

The maternal transmission of hypertension in this family suggested the mitochondrial involvement and led us to analyze the mitochondrial genome of matrilineal relatives. For this purpose, the DNA fragments spanning the entire mtDNA of the proband II-1 were PCR amplified, and each fragment was purified and subsequently analyzed by direct sequence. As shown in Table 2, the comparison of the resultant sequences with the Cambridge consensus sequence identified a number of nucleoside changes, belonging to the Eastern Asian haplogroup C.34 Of these nucleoside changes,

<p>| Table 1. Summary of Clinical Data for Some Members in 1 Han Chinese Family |
|------------------|--------------|------------------|------------------|------------------|</p>
<table>
<thead>
<tr>
<th>Subjects</th>
<th>Sex</th>
<th>Age of Test, y</th>
<th>Age of Onset, y</th>
<th>Systolic Pressure, mm Hg</th>
<th>Diastolic Pressure, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>II-1</td>
<td>F</td>
<td>65</td>
<td>60</td>
<td>180</td>
<td>110</td>
</tr>
<tr>
<td>II-2</td>
<td>M</td>
<td>68</td>
<td>NA</td>
<td>125</td>
<td>75</td>
</tr>
<tr>
<td>II-3</td>
<td>M</td>
<td>63</td>
<td>NA</td>
<td>130</td>
<td>75</td>
</tr>
<tr>
<td>III-1</td>
<td>M</td>
<td>40</td>
<td>NA</td>
<td>115</td>
<td>82</td>
</tr>
<tr>
<td>III-2</td>
<td>F</td>
<td>38</td>
<td>NA</td>
<td>100</td>
<td>70</td>
</tr>
<tr>
<td>III-3</td>
<td>M</td>
<td>41</td>
<td>36</td>
<td>140</td>
<td>110</td>
</tr>
<tr>
<td>III-4</td>
<td>F</td>
<td>39</td>
<td>NA</td>
<td>118</td>
<td>78</td>
</tr>
<tr>
<td>III-5</td>
<td>M</td>
<td>37</td>
<td>35</td>
<td>140</td>
<td>95</td>
</tr>
<tr>
<td>III-6</td>
<td>F</td>
<td>34</td>
<td>NA</td>
<td>126</td>
<td>76</td>
</tr>
<tr>
<td>IV-1</td>
<td>M</td>
<td>20</td>
<td>NA</td>
<td>122</td>
<td>70</td>
</tr>
<tr>
<td>IV-2</td>
<td>M</td>
<td>18</td>
<td>NA</td>
<td>116</td>
<td>74</td>
</tr>
<tr>
<td>IV-3</td>
<td>F</td>
<td>16</td>
<td>NA</td>
<td>112</td>
<td>72</td>
</tr>
</tbody>
</table>

M indicates male; F, female; NA, not applicable.

<p>| Table 2. MitDNA Variants in 1 Han Chinese Subject (II-1) With Hypertension |
|-------------------------------|------------------|------------------|</p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Position</th>
<th>Replacement</th>
<th>Conservation (H/B/M/X)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-Loop</td>
<td>73</td>
<td>A to G</td>
<td>Yes</td>
</tr>
<tr>
<td>249</td>
<td>DelA</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>310</td>
<td>T to CTC</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>489</td>
<td>T to C</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>16145</td>
<td>G to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>16223</td>
<td>C to T</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>16298</td>
<td>T to C</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>16519</td>
<td>T to C</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>12S rRNA</td>
<td>750</td>
<td>A to G</td>
<td>A/A/G/A</td>
</tr>
<tr>
<td>1438</td>
<td>A to G</td>
<td>A/A/A/G</td>
<td>Yes</td>
</tr>
<tr>
<td>ND1</td>
<td>3552</td>
<td>T to A</td>
<td>A/G/A/A</td>
</tr>
<tr>
<td>NC2</td>
<td>4401</td>
<td>A to G</td>
<td>A/A/A/A</td>
</tr>
<tr>
<td>ND2</td>
<td>4715</td>
<td>A to G</td>
<td>A/G/A/A</td>
</tr>
<tr>
<td>4769</td>
<td>A to G</td>
<td>A/G/A/A</td>
<td>Yes</td>
</tr>
<tr>
<td>5262</td>
<td>G to A (Ala to Thr)</td>
<td>A/M/V/F</td>
<td>Yes</td>
</tr>
<tr>
<td>CO1</td>
<td>5993</td>
<td>C to T</td>
<td>No</td>
</tr>
<tr>
<td>6338</td>
<td>A to G</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>6386</td>
<td>C to T</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>7028</td>
<td>C to T</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>7196</td>
<td>C to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>ATP6</td>
<td>8584</td>
<td>G to A (Ala to Thr)</td>
<td>A/V/V/I</td>
</tr>
<tr>
<td>8701</td>
<td>A to G (Thr to Ala)</td>
<td>T/S/L/Q</td>
<td>Yes</td>
</tr>
<tr>
<td>8860</td>
<td>A to G (Thr to Ala)</td>
<td>T/A/A/T</td>
<td>Yes</td>
</tr>
<tr>
<td>CO3</td>
<td>9540</td>
<td>T to C</td>
<td>Yes</td>
</tr>
<tr>
<td>9545</td>
<td>A to G</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>ND3</td>
<td>10398</td>
<td>A to G (Thr to Ala)</td>
<td>T/T/T/A</td>
</tr>
<tr>
<td>10400</td>
<td>C to T</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>ND4</td>
<td>10873</td>
<td>T to C</td>
<td>Yes</td>
</tr>
<tr>
<td>11447</td>
<td>G to A (Val to Met)</td>
<td>V/W/V/V</td>
<td>Yes</td>
</tr>
<tr>
<td>11719</td>
<td>G to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>11914</td>
<td>G to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>ND5</td>
<td>12705</td>
<td>C to T</td>
<td>Yes</td>
</tr>
<tr>
<td>13263</td>
<td>A to G</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>ND6</td>
<td>14318</td>
<td>T to C (Asn to Ser)</td>
<td>N/N/D/S</td>
</tr>
<tr>
<td>Cytb</td>
<td>14783</td>
<td>T to C</td>
<td>Yes</td>
</tr>
<tr>
<td>15043</td>
<td>G to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>15301</td>
<td>G to A</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>15326</td>
<td>A to G (Thr to Ala)</td>
<td>T/M/I/I</td>
<td>Yes</td>
</tr>
<tr>
<td>15487</td>
<td>T to C</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

*Conservation of amino acid for polypeptides or nucleotide for rRNAs in human (H), bovine (B), mouse (M), and X laevis (X).
†See http://www.mitomap.org and http://www.genpat.uu.se/mtDB/.
there were 8 polymorphisms in the D-loop region, 2 variants in the 12S rRNA gene, 1 variant in the 16S rRNA gene, 1 novel 4401A>G mutation in the spacer between tRNA^{Met} and tRNA^{Gln} genes, 20 silent mutations (1 novel and 19 known), and 8 missense mutations in protein-encoding genes.\textsuperscript{35} These missense mutations are 5262G>A (264A>T) in the ND2 gene, 8584G>A (20A>T), 8701A>G (59T>A), and 8860A>G (112T>A) in the ATP6 gene, 10398A>G (114T>A) in the ND3 gene, 11447G>A (230V>M) in the ND4 gene, 14318T>C (119N>S) in the ND6 gene, and 15326A>G (194T>A) in the Cytb gene. These variants in rRNAs and polypeptides were further evaluated by phylogenetic analysis of these variants and sequences from other organisms, including mouse,\textsuperscript{36} bovine,\textsuperscript{37} and Xenopus laevis.\textsuperscript{38} None of variants in the polypeptides and tRNAs were highly evolutionarily conserved and implicated to have significantly functional consequence.

However, the novel A to G transition at the position 4401 (4401A>G) mutation, as shown in Figure 2, lies at the junction of tRNA^{Met} at the H-strand and tRNA^{Gln} at the L-strand.\textsuperscript{19,20} Here the 5’ end of the flanking sequence is 4401T/TGAGAT in the tRNA^{Gln} gene, whereas the 5’ end of the flanking sequence is 4401T/TGAGAT in the tRNA^{Gln} gene.\textsuperscript{39} In fact, the processing of mitochondrial tRNAs requires the precise endonucleolytic cleavage at both 3’ and 5’ ends catalyzed by RNase P and 3’ endonuclease.\textsuperscript{20,40,41} Thus, the 4401A>G mutation may affect the reaction efficiency of the RNase P involved in tRNA^{Met} and tRNA^{Gln} 5’ end metabolism. The 4401A>G mutation was further assessed by phylogenetic analysis of this variant and sequences from mouse, bovine, and X laevis, as well as other 13 primates including Gorilla gorilla, Pan paniscus, Pan troglodytes, Pongo pygmaeus, Pongo abelii, Hylobates lar, Macaca mulatta, Macaca sylvanus, Papio hamadryas, Cebus albifrons, Tarsius bancanus, Nycticebus coucang, and Lemur catta (Genbank). In fact, the adenine at the 4401 position is extraordinarily conserved among these species. To determine whether the 4401A>G mutation is present in homoplasy, the fragments spanning the tRNA^{Met} and tRNA^{Gln} genes were PCR amplified and subsequently digested with BfaI, because the 4401A>G mutation creates the site for this restriction enzyme. As shown in Figure 2C, there was no detectable wild-type DNA in 4 matrilineal relatives, indicating that the 4401A>G mutation was present in homoplasy in these matrilineal relatives. In addition, this mutation was absent in 242 Han Chinese controls.

Mitochondrial tRNA Analysis

To examine whether the 4401A>G mutation affects the processing of the precursors in the tRNA^{Met} and tRNA^{Gln}, the steady-state levels of the tRNA^{Met} and tRNA^{Gln} genes were determined by isolating total mitochondrial RNA from cell lines derived from 2 affected individuals (II-1 and II-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family, separating them by a 10% polyacrylamide/7 mol/L urea gel, electrophotographing, and hybridizing with a nonradioactive DIG-labeled oligodeoxynucleotide probe specific for tRNA^{Met} and tRNA^{Gln}. After stripping the blots, the DIG-labeled oligodeoxynucleotide probes,
tRNAGln in the mutant cells were markedly decreased relative to the controls. In particular, the average levels of tRNAMet in the mutant cell lines derived from II-1 and III-3 ranged from ≈71% of controls after normalization to tRNAGly, ≈67% of controls after normalization to tRNALys, to ≈70% of controls after normalization to tRNA\textsubscript{Ser(UCN)}. Similarly, the average levels of tRNAGln in the mutant cell lines derived from II-1 and III-3 ranged from ≈75% of controls after normalization to tRNAGly, ≈71% of controls after normalization to tRNALys, to ≈70% of controls after normalization to tRNA\textsubscript{Ser(UCN)}.

**Mitochondrial Protein Synthesis Defect**
To examine whether a defect in mitochondrial translation occurred in lymphoblastoid cell lines carrying the 4401A>G mutation, cells derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family were labeled for 30 minutes with \(^{35}\)S-methionine-\(^{35}\)S-cysteine in methionine-free regular DMEM in the presence of 100 \(\mu\)g/mL of emetine to inhibit cytosolic protein synthesis.\textsuperscript{31} Figure 4A shows typical electrophoretic patterns of the mitochondrial translation products of the mutant and control cell lines. Patterns of the mtDNA-encoded polypeptides of the cells carrying the 4401A>G mutation were qualitatively identical in terms of electrophoretic mobility of the various polypeptides to those of the control cells and of 143B.TK\textsuperscript{−} cells. However, the cell lines carrying the 4401A>G mutation showed a clear tendency toward a decrease in the total rate of labeling of the mitochondrial translation products relative to those of control cell lines. Figure 4B shows a quantification of the results of a large number of labeling experiments and electrophoretic runs, which were carried out by the Image-Quant program of appropriate exposures of the fluorograms and normalization to data obtained for the 143B.TK\textsuperscript{−} sample. In fact, the overall rates of labeling of the mitochondrial translation products in the cell lines derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation were decreased 31.7% and 20.8%, with an average of 26.0% relative to the mean value measured in the control cell lines.

**Respiration Defects in the Cell Lines**
The endogenous respiration rates of cell lines derived from 2 affected individuals (II-1 and III-3) carrying the 4401A>G mutation and 2 married-in controls (II-2 and III-4) lacking this mutation in this Chinese family were measured by determining the \(O_2\) consumption rate in intact cells, as described previously.\textsuperscript{32} As shown in Figure 5A, the rate of total \(O_2\) consumption in the lymphoblastoid cell lines derived from 2 affected individuals (II-1 and III-3) ranged between ~74.9% and 80.6%, with an average of ~77.8% relative to the mean value measured in the control cell lines.

To investigate which of the enzyme complexes of the respiratory chain was affected in the mutant cell lines, \(O_2\) consumption measurements were carried out on digitonin-permeabilized cells using different substrates and inhibitors.\textsuperscript{33} As shown in Figure 5B, in the cell lines derived from 2 affected individuals, the rate of malate/glutamate-driven res-
Expiration, which depends on the activities of reduced nicotinamide-adenine dinucleotide:ubiquinone oxidoreductase (complex I), ubiquinol-cytochrome c reductase (complex III), and cytochrome c oxidase (complex IV), but usually reflects the rate-limiting activity of complex I, was very significantly decreased, relative to the average rate in the control cell lines, by 77% to 80% (on average).

Similarly, the rate of succinate/glycerol-3-phosphate–driven respiration, which depends on the activities of complexes III and IV but usually reflects the rate-limiting activity of complex III, was significantly affected in the mutant cell lines, relative to the average rate in the control cell lines, by 76% to 81% (on average). Furthermore, the rate of \( \text{N}, \text{N}, \text{N}’- \text{tetramethyl}-p \)-phenylenediamine/ascorbate-driven respiration, which reflects the activity of complex IV, exhibited a 78% to 82% reduction in complex IV activity (~80% on average) in the mutant cell lines relative to the average rate in the control cell lines.

**Discussion**

In the present study, we performed the clinical, genetic, and molecular characterization of a Han Chinese family with essential hypertension. The hypertension as a sole clinical phenotype was only present in all of the matrilineal relatives of this 4-generation pedigree. Clinical and genetic evaluations revealed the variable severity and age at onset in hypertension among 3 of 7 matrilineal relatives in this Chinese family. In particular, the age at onset in hypertension was 60, 36, and 35 years in 3 affected matrilineal relatives, with an average age of 44 years. The maternal transmission of hypertension in this family suggested that the mtDNA mutation(s) is 1 of the molecular bases for this disorder. Mutational analysis of the mitochondrial genome in this family identified 40 variants belonging to the Eastern Asian haplogroup C. Of these, 39 variants appeared to be polymorphisms, because these variants were not highly evolutionarily conserved and implicated to have significantly functional consequence. However, the homoplasmic A-to-G transition at position 4401 lies in the spacer immediately to the 5’ end of the tRNAMet and tRNAGln genes. Furthermore, the adenine at the 4401 position of the mitochondrial genomes is highly conserved among various primates. This mutation is present only in matrilineal relatives of this family in the homoplasmic form but not in the 242 Han Chinese controls, indicating that this mutation may be involved in the pathogenesis of hypertension.

In fact, 22 human mitochondrial tRNAs are interspersed among the other functional mitochondrial RNAs (2 rRNAs and 11 mRNAs encoding 13 polypeptide subunits of the oxidative phosphorylation complexes) on long precursor transcripts. Of these, 8 tRNAs, including tRNA\(^{\text{Glu}}\) and tRNA\(^{\text{Ser(UCN)}}\), are synthesized from the polycistrionic precursors of the L-strand, whereas the other 14 tRNAs, eg, tRNA\(^{\text{Met}}\), tRNA\(^{\text{Lys}}\), and tRNA\(^{\text{Gln}}\), are transcribed from the precursors of the H-strand transcripts. The processing of
precursors in mitochondrial tRNAs requires the precise endonucleolytic cleavage at both 5’ and 3’ ends. Extra nucleotides at their 5’ termini are removed by RNase P, whereas the excision of tRNAs from primary polycistronic mitochondrial transcripts at their 3’ end is catalyzed by the 3’ endonuclease. Thus, it is anticipated that the A-to-G transition at position 4401 in the H-strand may lead to defective tRNA\textsuperscript{Met} 5’ end processing in the H-strand transcripts, and the T-to-C transition at position 4401 may cause the reduced efficiency of the tRNA\textsuperscript{Gln} precursor 5’ end cleavage in the L-strand transcripts. There is increasing evidence showing that the 5’ and 3’ end processing defects arising from pathogenic mitochondrial tRNA mutations could contribute to clinical abnormalities. The deafness-associated 7445T>G mutation in the tRNA\textsuperscript{Ser(UCN)} gene and the cardiomyopathies-associated 4269A>G and 4295A>G mutations in the tRNA\textsuperscript{Thr} gene altered 3’ end processing efficiency of corresponding tRNAs. Similarly, the mitochondrial encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS)-associated 3243A>G and 3271T>C mutations and mitochondrial myopathy-associated 3302A>G mutation in the tRNA\textsuperscript{Leu(UUR)} led to the tRNA 5’ end processing defects. Alternatively, a taurine modification deficiency at the anticodon wobble position of tRNA\textsuperscript{Leu(UUR)} carrying the 3243A>G or 3271T>C mutation is involved in the decreased translation of ND6 with a high content of the UUG codon.

In the current study, compared with a control cell lacking the mutation, a ~30% reduction in the levels of tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} were observed in cells carrying the 4401A>G mutation. The lower levels of tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} in cells carrying the 4401A>G mutation most probably result from a defect in the 5’ end processing of tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} precursors. As a result, a shortage of the tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} leads to the reduced rate of mitochondrial protein synthesis. These defects appear to be responsible for the reduced activities of the mitochondrial respiratory chain. Subsequently, these defects lead to the reduction of ATP production and an increase of reactive oxygen species production. These mitochondrial dysfunctions likely contribute to the development of hypertension. However, the levels of total tRNA\textsuperscript{Met} and tRNA\textsuperscript{Gln} in mutant cells are above a proposed threshold, which is 30% of the control level of tRNA, to support a normal rate of mitochondrial translation. Thus, the homoplasmic form, mild mitochondrial dysfunctions, late onset, and incomplete penetrance of hypertension in this family carrying the 4401A>G mutation indicated that the 4401A>G mutation itself is insufficient to produce a clinical phenotype, as in the cases of hypertension-associated tRNA\textsuperscript{Met} 4435A>G mutation, deafness-associated 12S tRNA 1555A>G mutation, and Leber’s hereditary optic neuropathy-associated ND4 11778G>A mutation. The other modifier factors, eg, nuclear modifier genes, environmental factors, and personal lifestyles, also contribute to the development of hypertension in these subjects carrying the 4401A>G mutation. Therefore, the 4401A>G mutation, acting as an inherited risk factor, is involved in the development of hypertension in this Chinese family.

![Figure 5. Respiration assays. A, Average rates of endogenous O2 consumption per cell measured in different cell lines are shown, with error bars representing 2 SEMs. A total of 4 determinations were made on each of lymphoblastoid cell lines. B, Polarographic analysis of O2 consumption in digitonin-permeabilized cells of the various cell lines using different substrates and inhibitors. The analysis of O2 consumption in digitonin-permeabilized cells of the lymphoblastoid cell lines. Graph details and symbols are explained in the legend to Figure 3.](http://hyper.ahajournals.org/content/35/2/335)
Perspectives

The genetic and biochemical evidence indicate that the mtDNA 4401A→G mutation is involved in essential hypertension. The tissue specificity of this pathogenic mtDNA mutation is likely attributed to tissue-specific RNA processing or the involvement of nuclear modifier genes. The 4401A→G mutation should be added to the list of inherited risk factors for future molecular diagnosis for hypertension. Thus, our finding will provide new insights into the molecular mechanism, management, and treatment of maternally inherited hypertension. Future research should further explore the emerging link among hypertension, mitochondrial dysfunction, and their causative-effect relationship.

Sources of Funding

This work was supported by National Institutes of Health grants R01DK05230 and R01DC07696 from the National Institute on Deafness and Other Communication Disorders (to M-X.G.) and National Key Basic Research and Development Project 973 Fund 2007CB07403 (to S.W.).

Disclosures

None.

References

in eastern Asia and the peopling of Japan. Genome Res. 2004;84:
1832–1850.
35. Brandon MC, Lott MT, Nguyen KC, Spolim S, Navathe SB, Baldi P,
Wallace DC. MITOMAP: a human mitochondrial genome database–2004
Sequence and gene organization of mouse mitochondrial DNA. Cell.
The complete nucleotide sequence of the Rattus norvegicus mitochondrial
genome: cryptic signals revealed by comparative analysis between ver-
38. Roe A, Ma DP, Wilson RK, Wong JF. The complete nucleotide sequence
of the Xenopus laevis mitochondrial genome. J Biol Chem. 1985;260:
9759–9774.
39. Florentz C, Sohm B, Tryoen-Toth P, Putz J, Siessler M. Human mito-
chondrial tRNAs in health and disease. Cell Mol Life Sci. 2003;60:
1356–1375.
40. Holzmann J, Frank P, Löffler E, Bennett KL, Gerner C, Rossmanith W.
RNase P without RNA: identification and functional reconstitution of the
41. Levering L, Jacobs O, James M. In vitro 3’-end endonucleolytic pro-
cessing defect in a human mitochondrial tRNA Thr (UAC) precursor with the
U7445C substitution, which causes nonsyndromic deafness. Nucleic
42. Montoya J, Ojala D, Attardi G. Distinctive features of the 5’-terminal
sequences of the human mitochondrial mRNAs. Nature. 1981;290:
465–470.
43. Levering L, Mörl M, Florentz C. Mitochondrial tRNA 3’ end metabolism
44. Levering L, Gieger R, Florentz C. Pathology-related substitutions in
human mitochondrial tRNA Thr (UAC) reduce precursor 3’ end processing effi-
45. Bindoff LA, Howell N, Poulton J, McCullough DA, Morten KJ, Light-
owlers RN, Turnbull DM, Weber K. Abnormal RNA processing asso-
ciated with a novel tRNA mutation in mitochondrial DNA: a potential
46. Rossmannith W, Karwan RM. Impairment of tRNA processing by point
mutations in mitochondrial tRNA Thr (UAC) associated with mitochondrial
T. Codon-specific translational defect caused by a wobble modification
deficiency in mutant tRNA from a human mitochondrial disease. Proc
48. Postnov YV, Orlov SN, Budnikov YY, Doroschuk AD, Postnov AY.
Mitochondrial energy conversion disturbance with decrease in ATP pro-
duction as a source of systemic arterial hypertension. Pathophysiology.
2007;14:195–204.
49. Lopez-Campistrous A, Hao L, Xiang W, Ton D, Sernchuk P, Sander J,
Ellison MJ, Fernandez-Patron C. Mitochondrial dysfunction in the hyper-
tensive rat brain: respiratory complexes exhibit assembly defects in
50. Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive
Guan MX. Very low penetration of hearing loss in seven Han Chinese
pedigrees carrying the deafness-associated 12S rRNA A1555G mutation.
Gene. 2007;393:11–19.
52. Guan MX, Fischel-Ghodsian N, Attardi G. Nuclear background
determines biochemical phenotype in the deafness-associated mito-
53. Qu J, Zhou X, Zhang J, Zhao F, Sun YH, Yong Y, Wei QP, Cai W, West
CE, Guan MX. Extremely low penetrance of Leber’s hereditary optic
neuropathy (LHON) in eight Han Chinese families carrying the ND4
Failures in Mitochondrial tRNA^{Met} and tRNA^{Gln} Metabolism Caused by the Novel 4401A>G Mutation Are Involved in Essential Hypertension in a Han Chinese Family
Ronghua Li, Yuqi Liu, Zongbin Li, Li Yang, Shiwen Wang and Min-Xin Guan

*Hypertension*. 2009;54:329-337; originally published online June 22, 2009; doi: 10.1161/HYPERTENSIONAHA.109.129270

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/54/2/329

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Hypertension* is online at:
http://hyper.ahajournals.org/subscriptions/